Issue Date: August 3, 2009
Malaria Vaccine R&D Gets Funding
Dutch biopharmaceutical firm Crucell will collaborate with the PATH Malaria Vaccine Initiative (MVI) and the U.S. Agency for International Development (USAID) in an effort to bolster the immune response to a malaria vaccine in development. Crucell will use its recombinant adenoviruses, or viruses associated with the common cold, to deliver a malaria antigen to the immune system. USAID will fund the project. MVI has also expanded an existing contract with GenVec, awarding the Gaithersburg, Md.-based biotech firm $2 million to support preclinical studies of its adenovirus-based vaccines. Separately, NIH has awarded GenVec a $600,000 Small Business Innovation Research grant to support its malaria vaccine program.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society